A chimeric GB virus B encoding the hepatitis C virus hypervariable region 1 is infectious in vivo

被引:22
作者
Haqshenas, G.
Dong, X.
Netter, H.
Torresi, J.
Gowans, E. J.
机构
[1] Macfarlane Burnet Inst, Melbourne, Vic 3001, Australia
[2] Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia
[3] Univ Melbourne, Dept Med, RMH WH, Royal Melbourne Hosp,Ctr Clin Res Excellence, Parkville, Vic 3052, Australia
关键词
D O I
10.1099/vir.0.82467-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Two GB virus B (GBV-B) chimeric genomes, GBV-HVR and GBV-HVRh (with a hinge), containing the coding region of the immunodominant hypervariable region 1 (HVR1) of the E2 envelope protein of Hepatitis C virus (HCV) were constructed. Immunoblot analysis confirmed that HVR1 was anchored to the GBV-B E2 protein. To investigate the replication competence and in vivo stability of in vitro-generated chimeric RNA transcripts, two naive marmosets were inoculated intrahepatically with the transcripts. The GBV-HVR chimeric genome was detectable for 2 weeks post-inoculation (p.i.), whereas GBV-HVRh reverted to wild type 1 week p.i. Sequencing analysis of the HVR1 and flanking regions from GBV-HVR RNA isolated from marmoset serum demonstrated that the HVR1 insert remained unaltered in the GBV-HVR chimera for 2 weeks. Inoculation of a naive marmoset with serum collected at 1 week p.i. also resulted in viraemia and confirmed that the serum contained infectious particles. All animals cleared the infection by 3 weeks p.i. and remained negative for the remaining weeks. The chimera may prove useful for the in vivo examination of any HCV HVR1-based vaccine candidates.
引用
收藏
页码:895 / 902
页数:8
相关论文
共 42 条
[1]   Evolutionary study of HVR1 of E2 in chronic hepatitis C virus infection [J].
Alfonso, V ;
Flichman, DM ;
Sookoian, S ;
Mbayed, VA ;
Campos, RH .
JOURNAL OF GENERAL VIROLOGY, 2004, 85 :39-46
[2]   Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome [J].
Alter, HJ ;
Seeff, LB .
SEMINARS IN LIVER DISEASE, 2000, 20 (01) :17-35
[3]  
[Anonymous], FIELDS VIROLOGY
[4]   Replication of hepatitis C virus [J].
Bartenschlager, R ;
Lohmann, V .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :1631-1648
[5]   In vitro assay for neutralizing antibody to hepatitis C virus:: Evidence for broadly conserved neutralization epitopes [J].
Bartosch, B ;
Bukh, J ;
Meunier, JC ;
Granier, C ;
Engle, RE ;
Blackwelder, WC ;
Emerson, SU ;
Cosset, FL ;
Purcell, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) :14199-14204
[6]   Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus [J].
Beames, B ;
Chavez, D ;
Guerra, B ;
Notvall, L ;
Brasky, KM ;
Lanford, RE .
JOURNAL OF VIROLOGY, 2000, 74 (24) :11764-11772
[7]   Development of a GB virus B marmoset model and its validation with a novel series of hepatitis C virus NS3 protease inhibitors [J].
Bright, H ;
Carroll, AR ;
Watts, PA ;
Fenton, RJ .
JOURNAL OF VIROLOGY, 2004, 78 (04) :2062-2071
[8]   Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent [J].
Bukh, J ;
Apgar, CL ;
Yanagi, M .
VIROLOGY, 1999, 262 (02) :470-478
[9]   Host range studies of GB virus-B hepatitis agent, the closest relative of hepatitis C virus, in New World monkeys and chimpanzees [J].
Bukh, J ;
Apgar, CL ;
Govindarajan, S ;
Purcell, RH .
JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (04) :694-697
[10]   In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus [J].
Esumi, M ;
Zhou, YH ;
Tanoue, T ;
Tomoguri, T ;
Hayasaka, I .
VACCINE, 2002, 20 (25-26) :3095-3103